상세정보
Export to Refworks부가기능
Early Clinical Trial Design Recommendations in Oncology Based on Overall Success across Phases I, II, and III
상세 프로파일
| 자료유형 | 학위논문 |
|---|---|
| 서명/저자사항 | Early Clinical Trial Design Recommendations in Oncology Based on Overall Success across Phases I, II, and III. |
| 개인저자 | Ruppert Stark, Amy S. |
| 단체저자명 | The Ohio State University. Biostatistics. |
| 발행사항 | [S.l.]: The Ohio State University., 2017. |
| 발행사항 | Ann Arbor: ProQuest Dissertations & Theses, 2017. |
| 형태사항 | 204 p. |
| 기본자료 저록 | Dissertation Abstracts International 79-12B(E). Dissertation Abstract International |
| ISBN | 9780438097766 |
| 학위논문주기 | Thesis (Ph.D.)--The Ohio State University, 2017. |
| 일반주기 |
Source: Dissertation Abstracts International, Volume: 79-12(E), Section: B.
Adviser: Abigail Shoben. |
| 요약 | Conventionally, drug development has spanned three distinct phases, and the success rate for experimental drugs across phases has been less than 15% (Hay, Thomas, Craighead, Economides, and Rosenthal, 2014). Despite increased options for nonstan |
| 요약 | Phase I, II, and III trials were simulated for clinical scenarios defined by eight toxicity profiles and two nondecreasing efficacy profiles. Early results showed that correctly selecting the maximum tolerated dose (MTD) greatly impacted overall |
| 요약 | Based on our results, we make the following recommendations for design selection when data informing the shape of the dose-toxicity curve exist. If a large jump in toxicity between dose levels is expected, we recommend the standard 3+3 design, w |
| 일반주제명 | Biostatistics. |
| 언어 | 영어 |
| 바로가기 | 
: 이 자료의 원문은 한국교육학술정보원에서 제공합니다. |
